Audentes Therapeutics, Inc. Recorded Big Gain
Tue, Dec 03, 2019 at 05:30 PM
Audentes Therapeutics, Inc. (BOLD:NASDAQ) rocketted at $58.93, representing a gain of 106%. On Mon 02 Dec 19, BOLD:NASDAQ touched a New 2-Week Intraday High of $29.81. The stock got featured on our News Catalysts scanner on Tue 03 Dec 19 at 03:32 PM in the 'ACQUISITION' category. From Mon 11 Nov 19, the stock recorded 57.14% Up Days and 46.67% Green Days
The share price of the company has been moving sideways in recent weeks.
About Audentes Therapeutics, Inc. (BOLD:NASDAQ)
Audentes Therapeutics Inc is a biotechnology company. It is engaged in developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects.
Top 10 Gainers:
- Audentes Therapeutics, Inc. (BOLD:NASDAQ), 105.98%
- Quorum Health Corporation (QHC:NYSE), 65%
- Outlook Therapeutics, Inc. (OTLK:NASDAQ), 54.37%
- Motif Bio plc (MTFB:NASDAQ), 50.05%
- DarioHealth Corp. (DRIO:NASDAQ), 49.1%
- Sienna Biopharmaceuticals, Inc. (SNNA:NASDAQ), 47.06%
- iBio, Inc. (IBIO:NYSEMKT), 41.35%
- Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ), 41.01%
- Spirit Realty Capital, Inc. (SRC:NYSE), 40%
- Akerna Corp. (KERN:NASDAQ), 37.97%